Redefining Care: How Specialty Pharmacy is Shaping the Future of Healthcare
On today's episode we will be discussing specialty pharmacy with Dr. Ruchik Patel (Associate Director, Management Consulting at AESARA) and Dr. Sonalie Patel (Program Director & Clinical Pharmacist at Northwestern Medicine).Time Stamps:00:00 – 02:37 Introduction02:38 – 10:03 Overview of Specialty Pharmacy and Discussion on its Role10:04 – 12:22 Introduction and Discussion on the Role of Specialty Pharmacist12:41 – 15:28 Discussion on Current Challenges Faced by Specialty Pharmacists15:46 – 17:31 Response to Challenges in Specialty Pharmacy17:40 – 22:14 Real-World Experiences and Evidence Sharing22:31 – 24:55 Significance of Evidence Generation in Specialty Pharmacy25:20 – 27:09 Discussion on Additional Gaps and Opportunities in Specialty PharmacyEpisode Resources:Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis (https://onlinelibrary.wiley.com/doi/10.1111/liv.15075)Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs (https://www.journal-of-hepatology.eu/article/S0168-8278(23)00347-1/fulltext)Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011907/)Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings (https://www.journal-of-hepatology.eu/article/S0168-8278(21)00158-6/fulltext)Guest Bios:Ruchik Patel (https://www.linkedin.com/in/ruchiksp/)Sonalie Patel (https://www.linkedin.com/in/sonaliepatel/)
The impact of the Inflation Reduction Act on Healthcare & Pharma
On today's episode we will be discussing the inflation reduction act with Dr. Chad Patel (Head of US Strategic Partnerships) and Dr. Phoenix Riley (Visiting Scientist).Time Stamps:01:34 - 04:11 Impact of the Inflation Reduction Act (IRA) on the healthcare industry04:29 - 08:06 Medicare criteria for drug price negotiations08:22 - 11:26 Impact of IRA on the pharmaceutical industry11:37 - 13:33 Potential consequences of IRA on research initiatives13:49 - 16:49 Drug price reforms in Europe17:05 - 18:27 Pharma's response to the IRA18:41 - 20:37 Potential strategies in response to the IRAGuest Bios:Chad PatelChad has over 17 years of pharmaceutical industry experience and leadership primarily focused on field/payer facing roles in health economics and outcomes research (HEOR), medical, and market access.Chad has technical expertise in several therapeutic areas and focused on real world evidence generation and communication to meet US payers evidence needs to support access and reimbursement. As a result, he helped to secure > $10 million dollars in product revenues, partnered to gain or maintain formulary access for various products > 20 payer accounts. Chad is an author on over 20 presentations and publications.Chad has demonstrated the ability to lead and work collaboratively with teams while strategically generating and communicating key clinical and health economic evidence needs which he now uses to help clients meet their goals.Prior to re-joining AESARA, Chad worked at Genentech, Bristol-Myers Squibb Co, Astellas Inc, Eli Lilly and most recently, Genentech. Chad is a pharmacist by training receiving his Doctor of Pharmacy from the University of Mississippi.Phoenix RileyPhoenix recently graduated with her Doctor of Pharmacy and Master of Science in Clinical Research degrees from Campbell University College of Pharmacy and Health Sciences. She also holds a Bachelor of Science degree in Chemistry from University of North Carolina Wilmington.Phoenix has experience in market access and HEOR specifically working at Grifol’s where she gained experience in evidence gap analysis and contributing towards clinical utilization data abstraction. Furthermore, Phoenix has completed a cost-analysis of direct oral anticoagulants versus enoxaparin for prophylaxis of acute venous thromboembolism in acute medically ill patients, where she gained experience with developing economic Markov models using Treeage Pro.
Integrated Evidence Generation Planning I Gavin Outteridge
In our inaugural episode we are discussing integrated evidence generation planning (IEGP) in the pharmaceutical industry featuring our AESARA Europe Managing Director, Gavin Outteridge.Time Stamps:1:13 - 7:16 Defining IEGP and its Benefits7:24 - 11:00 Shortcomings in the current evidence generation approach11:13 - 14:45 Impact on patient outcomes15:04 - 20:29 Challenges to the IEGP process20:43 - 23:35 Use of technology to improve process & closing commentsResources:Developing an integrated strategy for evidence generation (https://tinyurl.com/43zuamvv)